Adocia SA (LON:0QAI)

Market Cap	77.54M +14.9%
Revenue (ttm)	11.04M +258.4%
Net Income	-8.33M
EPS	-0.51
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112
Average Volume	4,915
Open	4.615
Previous Close	4.805
Day's Range	4.500 - 4.615
52-Week Range	3.150 - 12.240
Beta	-0.07
RSI	25.16
Earnings Date	Apr 21, 2026

About Adocia

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combinati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 77
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAI

Financial Performance

In 2024, Adocia's revenue was 12.12 million, an increase of 100.43% compared to the previous year's 6.05 million. Losses were -9.32 million, -55.95% less than in 2023.

Financial numbers in EUR